ACCC's Center for Provider Education’s Prostate Cancer Best Practices Project is a new resource for community cancer programs to help develop prostate-specific cancer services in their home communities.
Archived Webinar: "Guide to Best Practices in a Comprehensive Prostate Cancer Program II"
On August 3, 2010, ACCC offered a live web presentation about best practices in a comprehensive prostate cancer program. The webinar outlined the process and structures used by community-based cancer programs to initiate and grow their successful prostate-specific programs. Learn how to open lines of communication among providers and develop a collaborative team approach to care. This webinar is made possible by sponsorship from sanofi-aventis US.
Facilitator: Mary Lou Bowers, MBA, The Pritchard Group.
Guide to Best Practices in a Comprehensive Prostate Cancer Program
This document is designed to assist community centers by outlining the process and structures that successful community-based prostate-specific cancer programs throughout the U.S. have used to initiate and grow their prostate cancer programs. It serves as a resource for community programs in identifying the need for prostate-specific care in their communities, opening lines of communication among providers, developing a collaborative team approach to care, and providing guidance in planning and implementing a successful multidisciplinary prostate cancer program.
The Journal of the Association of Community Cancer Centers
September/October 2009 Vol. 24 No. 5
Developing a Multispecialty Prostate Cancer Clinic
Prostate Cancer News/Alerts
March 9-12, 2011, the Prostate Cancer Research Program's (PCRP's) Innovative Minds in Prostate Cancer Today (IMPaCT) Conference was held in Orlando, Fla. Conference proceedings are available here.
The U.S. Preventive Services Task Force’s draft recommendation statement, released in October 2011, recommended against routine use of the PSA test for screening for prostate cancer. The recommendation applies to men in the U.S. population who do not have symptoms that are highly suspicious for prostate cancer.